GlassScriptPhysician profile
Sanjay K Singh
NPI 1952403362
$2,872.82
in general payments reported to CMS, 2019-2025
12 companies · $708 in 2025
The $708 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $78.83 · 2021: $156 · 2022: $401 · 2023: $612 · 2024: $713 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $756.47 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $531.63 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $518.45 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $260.20 | 2022-2025 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $252.73 | 2021-2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.56 | 2020-2023 | Caplyta |
| Neurocrine Biosciences, INC. | $145.54 | 2023-2025 | Ingrezza |
| Abbvie INC. | $95.59 | 2021-2024 | Vraylar |
| Bioxcel Therapeutics, INC. | $64.84 | 2023 | Igalmi |
| Neurelis, INC. | $24.41 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.89 | 2019 | |
| Shire North American Group INC | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.